Home > Result Summaries: Compounds > Haemophilus influenzae Type b Vaccine > Result Summary for 112933_

Result Summary for 112933_

Result Summary

Protocol ID:	112933_
Clinical Study ID:	112933
Official Title:	Booster vaccination with pneumococcal vaccine GSK1024850A or Prevenar™ co-administered with Hiberix™ in children primed with the same vaccines
Phase:	phase 3
Study Indications or Diseases:	Hib
Generic Name:	Haemophilus influenzae Type b Vaccine
Trade/Product Name:	Hiberix
Approved Drug Label:	http://www.gsk.com/products.html
Results Summary:	Click here to download result summary.
Citations:	Kim CH et al. (2011) Response to Primary and Booster vaccination with 10-valent Pneumococcal nontypeable Haemophilus influenzae Protein D conjugate vaccine in Korean Infants. Pediatr Infect Dis J. 30(12):e235-e243. Kim CH et al. Immunogenicity and safety of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Korean children. Abstract presented at the Korean Society of Pediatric Infectious Diseases - 2011 Spring Conference. Seoul, South Korea, 7-11 June 2011. Kim JS et al. Safety and reactogenicity of booster vaccination with 10-valent pneumococcal non-typeable Haemophilus influenzae protein d conjugate vaccine (PHiD-CV) in Korean children. Abstract presented at the 8th International Symposium on Antimicrobial Agents and Resistance (ISAAR). Seoul, Republic of Korea, 6-8 April 2011. Kim KH et al. Immunogenicity of booster vaccination with 10-valent pneumococcal non-typeable Haemophilus influenzae protein d conjugate vaccine (PHiD-CV) in Korean children. Abstract presented at the 8th International Symposium on Antimicrobial Agents and Resistance (ISAAR). Seoul, Republic of Korea, 6-8 April 2011.